Abstract
BackgroundMR-guided online adaptive stereotactic body radiation therapy (SBRT) for prostate cancer aims to reduce toxicity by full compensation of interfractional uncertainties. However, the process of online adaptation currently takes approximately 45 min during which intrafractional movements remain unaccounted for. This study aims to analyze the dosimetric benefit of online adaptation and to evaluate its robustness over the duration of one treatment fraction.MethodsBaseline MR-scans at a MR-linear accelerator were acquired for ten healthy male volunteers for generation of mock-prostate SBRT plans with a dose prescription of 5 × 7.25 Gy. On a separate day, online MR-guided adaptation (ViewRay® MRIdian) was performed, and thereafter MR images were acquired every 15 min for 1 h to assess the stability of the adapted plan.ResultsA dosimetric benefit of online MR-guided adaptive re-planning was observed in 90% of volunteers. The median D95CTV- and D95PTV-coverage was improved from 34.8 to 35.5 Gy and from 30.7 to 34.6 Gy, respectively. Improved target coverage was not associated with higher dose to the organs at risk, most importantly the rectum (median D1ccrectum baseline plan vs. adapted plan 33.3 Gy vs. 32.3 Gy). The benefit of online adaptation remained stable over 45 min for all volunteers. However, at 60 min, CTV-coverage was below a threshold of 32.5 Gy in 30% of volunteers (30.6 Gy, 32.0 Gy, 32.3 Gy).ConclusionThe dosimetric benefit of MR-guided online adaptation for prostate SBRT was robust over 45 min in all volunteers. However, intrafractional uncertainties became dosimetrically relevant at 60 min and we therefore recommend verification imaging before delivery of MR-guided online adapted SBRT.
Highlights
Stereotactic body radiotherapy (SBRT) has been implemented in the treatment of localized prostate cancer and evaluated in multiple prospective phase II trials, which have shown comparable outcomes to other treatment modalities both, with regard to toxicities, and to long-term recurrence-free survival [1,2,3,4]
stereotactic body radiation therapy (SBRT) today represents an alternative to conventionally fractionated radiotherapy for low to intermediate risk prostate cancer at clinics with appropriate technology, physics, and clinical expertise according to the NCCN guidelines v2.2020 [5,6,7]
clinical target volume (CTV)- and PTVcoverage were improved by Magnetic resonance (MR)-guided online adaptation in 90% of volunteers (Fig. 2 baseline vs. adapted plan D95CTV, Table 1)
Summary
Stereotactic body radiotherapy (SBRT) has been implemented in the treatment of localized prostate cancer and evaluated in multiple prospective phase II trials, which have shown comparable outcomes to other treatment modalities both, with regard to toxicities, and to long-term recurrence-free survival [1,2,3,4]. Online plan-adaptation can yield reduced planning target volume (PTV) margins by accounting for movements in both, the clinical target volume (CTV) and organs at risk (OAR) in close proximity. It promises to compensate for both, systematic anatomic changes, like prostate swelling, as well as random changes, such as inter- and intrafractional rectal and bladder fillings. MR-guided online adaptive stereotactic body radiation therapy (SBRT) for prostate cancer aims to reduce toxicity by full compensation of interfractional uncertainties. This study aims to analyze the dosimetric benefit of online adaptation and to evaluate its robustness over the duration of one treat‐ ment fraction
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
